$SPRY News

Can ARS Pharma's New CEO Unlock Neffy's Potential?

ARS Pharmaceuticals CEO Richard Lowenthal To Depart, Effective July 6; President Donn Casale Named Successor, Effective July 7

ARS Pharma: Strong Growth Meets A Coverage Wall

ARS Pharma Reaffirms 2027 Breakeven Goal Despite Missing July Neffy Coverage Wins

Leerink Partners Maintains Outperform on ARS Pharmaceuticals, Lowers Price Target to $24

ARS Pharmaceuticals (SPRY) Stock Sinks After-Hours After Commercial Update On Neffy Coverage

ARS Pharma Lowers 2026 Cash Operating Expense Guidance To $248M And Reaffirms Path To Cash-Flow Breakeven In 2027

ARS Pharmaceuticals Continues To Reduce Cash-Based Operating Expenses After No New Commercial Formulary Additions Or Coverage Decisions Have Been Issued For Neffy In The Latest Cycle

How The Evolving Story For ARS Pharmaceuticals (SPRY) Could Shape Future Valuation

Drew Brees Collaborates with ARS Pharmaceuticals to Raise Awareness About Living Life with Severe Allergies

Cantor Fitzgerald Maintains Overweight on ARS Pharmaceuticals, Raises Price Target to $30

ARS Pharmaceuticals: Still A Buy As Neffy Access Improves

ARS Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary

ARS Pharmaceuticals Inc (SPRY) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ...

ARS Pharmaceuticals, Inc. (SPRY) Q1 2026 Earnings Call Transcript

Third Point Increases Stake In ARS Pharmaceuticals To 1,000,000 Shares

ARS Pharmaceuticals Q1 Earnings Call Highlights

ARS Pharmaceuticals (NASDAQ:SPRY) Reports Revenue Growth in Q1 2026, Net Loss Widens on Commercial Investment

ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update

ARS Pharmaceuticals Q1 2026 Earnings Call Transcript